Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Medicine
Published in: Clinical and Translational Medicine 1/2020

Open Access 01-12-2020 | Arterial Occlusive Disease | Review

Unveiling ncRNA regulatory axes in atherosclerosis progression

Authors: Estanislao Navarro, Adrian Mallén, Josep M. Cruzado, Joan Torras, Miguel Hueso

Published in: Clinical and Translational Medicine | Issue 1/2020

Login to get access

Abstract

Completion of the human genome sequencing project highlighted the richness of the cellular RNA world, and opened the door to the discovery of a plethora of short and long non-coding RNAs (the dark transcriptome) with regulatory or structural potential, which shifted the balance of pathological gene alterations from coding to non-coding RNAs. Thus, disease risk assessment currently has to also evaluate the expression of new RNAs such as small micro RNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), competing endogenous RNAs (ceRNAs), retrogressed elements, 3′UTRs of mRNAs, etc. We are interested in the pathogenic mechanisms of atherosclerosis (ATH) progression in patients suffering Chronic Kidney Disease, and in this review, we will focus in the role of the dark transcriptome (non-coding RNAs) in ATH progression. We will focus in miRNAs and in the formation of regulatory axes or networks with their mRNA targets and with the lncRNAs that function as miRNA sponges or competitive inhibitors of miRNA activity. In this sense, we will pay special attention to retrogressed genomic elements, such as processed pseudogenes and Alu repeated elements, that have been recently seen to also function as miRNA sponges, as well as to the use or miRNA derivatives in gene silencing, anti-ATH therapies. Along the review, we will discuss technical developments associated to research in lncRNAs, from sequencing technologies to databases, repositories and algorithms to predict miRNA targets, as well as new approaches to miRNA function, such as integrative or enrichment analysis and their potential to unveil RNA regulatory networks.
Literature
1.
Hueso M et al (2018) ALUminating the path of atherosclerosis progression: chaos theory suggests a role for Alu repeats in the development of atherosclerotic vascular disease. Int J Mol Sci 19(6):1734PubMedCentralCrossRef
2.
3.
4.
5.
6.
Koenig W (2013) High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int J Cardiol 168(6):5126–5134PubMedCrossRef
7.
Vitali C, Khetarpal SA, Rader DJ (2017) HDL cholesterol metabolism and the risk of CHD: new insights from human genetics. Curr Cardiol Rep 19(12):132PubMedCrossRef
8.
9.
Dron JS, Ho R, Hegele RA (2017) Recent advances in the genetics of atherothrombotic disease and its determinants. Arterioscler Thromb Vasc Biol 37(10):e158–e166PubMedCrossRef
10.
Tabaei S, Tabaee SS (2019) DNA methylation abnormalities in atherosclerosis. Artif Cells Nanomed Biotechnol 47(1):2031–2041PubMedCrossRef
11.
Aavik E, Babu M, Yla-Herttuala S (2019) DNA methylation processes in atheosclerotic plaque. Atherosclerosis 281:168–179PubMedCrossRef
12.
Chen HH, Stewart AF (2016) Transcriptomic signature of atherosclerosis in the peripheral blood: fact or fiction? Curr Atheroscler Rep 18(12):77PubMedCrossRef
13.
Fan J et al (2018) Genomic and transcriptomic analysis of hypercholesterolemic rabbits: progress and perspectives. Int J Mol Sci 19(11):3512PubMedCentralCrossRef
14.
Consortium, E.P. (2012) An integrated encyclopedia of DNA elements in the human genome. Nature 489(7414):57–74CrossRef
15.
16.
17.
18.
Litman T, Stein WD (2019) Obtaining estimates for the ages of all the protein-coding genes and most of the ontology-identified noncoding genes of the human genome, assigned to 19 phylostrata. Semin Oncol 46(1):3–9PubMedCrossRef
19.
Pertea M et al (2018) CHESS: a new human gene catalog curated from thousands of large-scale RNA sequencing experiments reveals extensive transcriptional noise. Genome Biol 19(1):208PubMedPubMedCentralCrossRef
20.
21.
22.
Johnson JM et al (2005) Dark matter in the genome: evidence of widespread transcription detected by microarray tiling experiments. Trends Genet 21(2):93–102PubMedCrossRef
23.
24.
25.
Ma L, Bajic VB, Zhang Z (2013) On the classification of long non-coding RNAs. RNA Biol 10(6):925–933PubMedCrossRef
26.
Siomi MC et al (2011) PIWI-interacting small RNAs: the vanguard of genome defence. Nat Rev Mol Cell Biol 12(4):246–258PubMedCrossRef
27.
Hombach S, Kretz M (2016) Non-coding RNAs: classification, biology and functioning. Adv Exp Med Biol 937:3–17PubMedCrossRef
28.
29.
30.
Dey BK, Mueller AC, Dutta A (2014) Long non-coding RNAs as emerging regulators of differentiation, development, and disease. Transcription 5(4):e944014PubMedPubMedCentralCrossRef
31.
Prasanth KV, Spector DL (2007) Eukaryotic regulatory RNAs: an answer to the ‘genome complexity’ conundrum. Genes Dev 21(1):11–42PubMedCrossRef
32.
Waller P, Blann AD (2019) Non-coding RNAs—a primer for the laboratory scientist. Br J Biomed Sci 76:157–165PubMedCrossRef
33.
Consortium, E.P. et al (2007) Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447(7146):799–816CrossRef
34.
Carninci P, Yasuda J, Hayashizaki Y (2008) Multifaceted mammalian transcriptome. Curr Opin Cell Biol 20(3):274–280PubMedCrossRef
35.
36.
37.
38.
Crick FH (1958) On protein synthesis. Symp Soc Exp Biol 12:138–163PubMed
39.
Brenner S, Jacob F, Meselson M (1961) An unstable intermediate carrying information from genes to ribosomes for protein synthesis. Nature 190:576–581PubMedCrossRef
40.
Burke AC, Huff MW (2018) Regression of atherosclerosis: lessons learned from genetically modified mouse models. Curr Opin Lipidol 29(2):87–94PubMedCrossRef
41.
42.
43.
Lander ES et al (2001) Initial sequencing and analysis of the human genome. Nature 409(6822):860–921PubMedCrossRef
44.
45.
Tang F et al (2009) mRNA-Seq whole-transcriptome analysis of a single cell. Nat Methods 6(5):377–382PubMedCrossRef
46.
Karsch-Mizrachi I et al (2018) The international nucleotide sequence database collaboration. Nucleic Acids Res 46(D1):D48–D51PubMedCrossRef
47.
O’Leary NA et al (2016) Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. Nucleic Acids Res 44(D1):D733–D745CrossRefPubMed
48.
Yandell M, Ence D (2012) A beginner’s guide to eukaryotic genome annotation. Nat Rev Genet 13(5):329–342PubMedCrossRef
49.
50.
Sayers EW et al (2019) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 47(D1):D23–D28PubMedCrossRef
51.
Sanger F, Coulson AR (1975) A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. J Mol Biol 94(3):441–448PubMedCrossRef
52.
Sanger F, Coulson AR (1978) The use of thin acrylamide gels for DNA sequencing. FEBS Lett 87(1):107–110PubMedCrossRef
53.
Prober JM et al (1987) A system for rapid DNA sequencing with fluorescent chain-terminating dideoxynucleotides. Science 238(4825):336–341PubMedCrossRef
54.
Ciora T, Denefle P, Mayaux JF (1991) Rapid one-step automated sequencing reactions for 16 DNA samples using Taq polymerase and fluorescent primers. Nucleic Acids Res 19(1):188PubMedPubMedCentralCrossRef
55.
Rosenthal A, Charnock-Jones DS (1993) Linear amplification sequencing with dye terminators. Methods Mol Biol 23:281–296PubMed
56.
57.
Kono N, Arakawa K (2019) Nanopore sequencing: review of potential applications in functional genomics. Dev Growth Differ 61(5):316–326PubMedCrossRef
58.
Buermans HP, den Dunnen JT (2014) Next generation sequencing technology: advances and applications. Biochim Biophys Acta 1842(10):1932–1941PubMedCrossRef
59.
60.
Souquere S et al (2010) Highly ordered spatial organization of the structural long noncoding NEAT1 RNAs within paraspeckle nuclear bodies. Mol Biol Cell 21(22):4020–4027PubMedPubMedCentralCrossRef
61.
Adams MD et al (1991) Complementary DNA sequencing: expressed sequence tags and human genome project. Science 252(5013):1651–1656PubMedCrossRef
62.
Adams MD et al (1992) Sequence identification of 2,375 human brain genes. Nature 355(6361):632–634PubMedCrossRef
63.
Okubo K et al (1992) Large scale cDNA sequencing for analysis of quantitative and qualitative aspects of gene expression. Nat Genet 2(3):173–179PubMedCrossRef
64.
Takahashi N, Ko MS (1993) The short 3′-end region of complementary DNAs as PCR-based polymorphic markers for an expression map of the mouse genome. Genomics 16(1):161–168PubMedCrossRef
65.
Kotake Y et al (2011) Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene 30(16):1956–1962CrossRefPubMed
66.
Burd CE et al (2010) Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk. PLoS Genet 6(12):e1001233PubMedPubMedCentralCrossRef
67.
Sarkar D et al (2017) Multiple isoforms of ANRIL in melanoma cells: structural complexity suggests variations in processing. Int J Mol Sci 18(7):1378PubMedCentralCrossRef
68.
Holdt LM, Teupser D (2018) Long noncoding RNA ANRIL: Lnc-ing genetic variation at the chromosome 9p21 locus to molecular mechanisms of atherosclerosis. Front Cardiovasc Med 5:145PubMedPubMedCentralCrossRef
69.
70.
71.
72.
73.
74.
75.
76.
77.
Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120(1):15–20PubMedCrossRef
78.
Vidigal JA, Ventura A (2015) The biological functions of miRNAs: lessons from in vivo studies. Trends Cell Biol 25(3):137–147PubMedCrossRef
79.
Grassi E et al (2018) Choice of alternative polyadenylation sites, mediated by the RNA-binding protein Elavl3, plays a role in differentiation of inhibitory neuronal progenitors. Front Cell Neurosci 12:518PubMedCrossRef
80.
Chen LL (2016) Linking long noncoding RNA localization and function. Trends Biochem Sci 41(9):761–772PubMedCrossRef
81.
Liaw HH et al (2013) Differential microRNA regulation correlates with alternative polyadenylation pattern between breast cancer and normal cells. PLoS ONE 8(2):e56958PubMedPubMedCentralCrossRef
82.
Ogorodnikov A, Kargapolova Y, Danckwardt S (2016) Processing and transcriptome expansion at the mRNA 3′ end in health and disease: finding the right end. Pflugers Arch 468(6):993–1012PubMedPubMedCentralCrossRef
83.
Wanke KA, Devanna P, Vernes SC (2018) Understanding neurodevelopmental disorders: the promise of regulatory variation in the 3′UTRome. Biol Psychiatry 83(7):548–557PubMedCrossRef
84.
Xiao R et al (2019) Adipogenesis associated Mth938 domain containing (AAMDC) protein expression is regulated by alternative polyadenylation and microRNAs. FEBS Lett 593(14):1724–1734PubMedCrossRef
85.
Bruhn O et al (2016) Length variants of the ABCB1 3′-UTR and loss of miRNA binding sites: possible consequences in regulation and pharmacotherapy resistance. Pharmacogenomics 17(4):327–340PubMedCrossRef
86.
87.
Hueso M et al (2019) An exonic switch regulates differential accession of microRNAs to the Cd34 transcript in atherosclerosis progression. Genes (Basel) 10(1):70CrossRef
88.
89.
Thomas MR, Lip GY (2017) Novel risk markers and risk assessments for cardiovascular disease. Circ Res 120(1):133–149PubMedCrossRef
90.
91.
92.
Papadopoulos T et al (2015) miRNAs in urine: a mirror image of kidney disease? Expert Rev Mol Diagn 15(3):361–374PubMedCrossRef
93.
Chevillet JR et al (2015) Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc Natl Acad Sci USA 111(41):14888–14893CrossRef
94.
Johnson JL (2019) Elucidating the contributory role of microRNA to cardiovascular diseases (a review). Vasc Pharmacol 114:31–48CrossRef
95.
Yao Y et al (2019) Platelet-derived exosomal MicroRNA-25-3p inhibits coronary vascular endothelial cell inflammation through Adam10 via the NF-kappaB signaling pathway in ApoE(-/-) mice. Front Immunol 10:2205PubMedPubMedCentralCrossRef
96.
Yu DR et al (2020) MicroRNA-9 overexpression suppresses vulnerable atherosclerotic plaque and enhances vascular remodeling through negative regulation of the p38MAPK pathway via OLR1 in acute coronary syndrome. J Cell Biochem 121:49–62PubMedCrossRef
97.
Xu CX et al. (2019) MiR-647 promotes proliferation and migration of ox-LDL-treated vascular smooth muscle cells through regulating PTEN/PI3K/AKT pathway. Eur Rev Med Pharmacol Sci 23(16):7110–7119PubMed
98.
99.
Wu W et al (2019) Overexpression of miR-223 inhibits foam cell formation by inducing autophagy in vascular smooth muscle cells. Am J Transl Res 11(7):4326–4336PubMedPubMedCentral
100.
Zhou Z et al (2019) MicroRNA-30-3p suppresses inflammatory factor-induced endothelial cell injury by targeting TCF21. Mediators Inflamm 2019:1342190PubMedPubMedCentral
101.
Han Z et al (2019) MicroRNA-99a-5p alleviates atherosclerosis via regulating Homeobox A1. Life Sci 232:116664PubMedCrossRef
102.
Jiang L et al (2020) Inhibition of microRNA-103 attenuates inflammation and endoplasmic reticulum stress in atherosclerosis through disrupting the PTEN-mediated MAPK signaling. J Cell Physiol 235(1):380–393PubMedCrossRef
103.
Zhang W et al (2019) MicroRNA-451 inhibits vascular smooth muscle cell migration and intimal hyperplasia after vascular injury via Ywhaz/p38 MAPK pathway. Exp Cell Res 379(2):214–224PubMedCrossRef
104.
Yang L, Gao C (2019) MiR-590 inhibits endothelial cell apoptosis by inactivating the TLR4/NF-kappaB pathway in atherosclerosis. Yonsei Med J 60(3):298–307PubMedPubMedCentralCrossRef
105.
Shi X, Chen X (2019) Effect of microRNA-370 on coronary atherosclerosis and its underlying mechanism. Exp Ther Med 17(1):115–122PubMed
106.
Yin J, Hou X, Yang S (2019) microRNA-338-3p promotes ox-LDL-induced endothelial cell injury through targeting BAMBI and activating TGF-beta/Smad pathway. J Cell Physiol 234(7):11577–11586PubMedCrossRef
107.
Iaconetti C et al (2015) Down-regulation of miR-23b induces phenotypic switching of vascular smooth muscle cells in vitro and in vivo. Cardiovasc Res 107(4):522–533PubMedCrossRef
108.
Qu Y, Zhang N (2018) miR-365b-3p inhibits the cell proliferation and migration of human coronary artery smooth muscle cells by directly targeting ADAMTS1 in coronary atherosclerosis. Exp Ther Med 16(5):4239–4245PubMedPubMedCentral
109.
Yang S et al (2018) MicroRNA-23a-5p promotes atherosclerotic plaque progression and vulnerability by repressing ATP-binding cassette transporter A1/G1 in macrophages. J Mol Cell Cardiol 123:139–149PubMedCrossRef
110.
Qin B et al (2018) MicroRNA-142-3p induces atherosclerosis-associated endothelial cell apoptosis by directly targeting rictor. Cell Physiol Biochem 47(4):1589–1603PubMedCrossRef
111.
Su G et al (2018) Downregulation of miR-34a promotes endothelial cell growth and suppresses apoptosis in atherosclerosis by regulating Bcl-2. Heart Vessels 33(10):1185–1194PubMedCrossRef
112.
113.
Yin D et al (2018) Pro-angiogenic role of LncRNA HULC in microvascular endothelial cells via sequestrating miR-124. Cell Physiol Biochem 50(6):2188–2202PubMedCrossRef
114.
Tian D et al (2018) MiR-370 inhibits vascular inflammation and oxidative stress triggered by oxidized low-density lipoprotein through targeting TLR4. J Cell Biochem 119(7):6231–6237PubMedCrossRef
115.
Ahmadzada T, Reid G, McKenzie DR (2018) Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer. Biophys Rev 10(1):69–86PubMedPubMedCentralCrossRef
116.
117.
118.
Bernardo BC et al (2015) miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart. Future Med Chem 7(13):1771–1792PubMedCrossRef
119.
Pradhan-Nabzdyk L et al (2014) Current siRNA targets in atherosclerosis and aortic aneurysm. Discov Med 17(95):233–246PubMedPubMedCentral
120.
Zhou LY et al (2019) Current RNA-based therapeutics in clinical trials. Curr Gene Ther 19(3):172–196PubMedCrossRef
121.
122.
Gallant-Behm CL et al (2018) A synthetic microRNA-92a inhibitor (MRG-110) accelerates angiogenesis and wound healing in diabetic and nondiabetic wounds. Wound Repair Regen 26(4):311–323PubMedCrossRef
123.
Gallant-Behm CL et al (2019) A MicroRNA-29 Mimic (Remlarsen) represses extracellular matrix expression and fibroplasia in the skin. J Invest Dermatol 139(5):1073–1081PubMedCrossRef
124.
Gomez IG et al (2015) Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J Clin Invest 125(1):141–156PubMedCrossRef
125.
Loyer X et al (2015) MicroRNAs as therapeutic targets in atherosclerosis. Expert Opin Ther Targets 19(4):489–496PubMedCrossRef
126.
Jiang L et al (2019) miR-449a induces EndMT, promotes the development of atherosclerosis by targeting the interaction between AdipoR2 and E-cadherin in Lipid Rafts. Biomed Pharmacother 109:2293–2304PubMedCrossRef
127.
Guo J et al (2018) The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells. EBioMedicine 35:204–221PubMedPubMedCentralCrossRef
128.
129.
Ickenstein LM, Garidel P (2019) Lipid-based nanoparticle formulations for small molecules and RNA drugs. Expert Opin Drug Deliv 16(11):1205–1226PubMedCrossRef
130.
131.
132.
Islas JF, Moreno-Cuevas JE (2018) A MicroRNA perspective on cardiovascular development and diseases: an update. Int J Mol Sci 19(7):2075PubMedCentralCrossRef
133.
Chen Y, Gao DY, Huang L (2015) In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev 81:128–141PubMedCrossRef
134.
135.
Wang Z et al (2019) Anti-GPC3 antibody tagged cationic switchable lipid-based nanoparticles for the Co-delivery of anti-miRNA27a and sorafenib in liver cancers. Pharm Res 36(10):145PubMedCrossRef
136.
Reid G et al (2016) Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. Epigenomics 8(8):1079–1085PubMedCrossRef
137.
Jackson AL, Linsley PS (2010) Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 9(1):57–67PubMedCrossRef
138.
van Zandwijk N et al (2017) Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol 18(10):1386–1396PubMedCrossRef
139.
140.
Grote P, Herrmann BG (2015) Long noncoding RNAs in organogenesis: making the difference. Trends Genet 31(6):329–335PubMedCrossRef
141.
142.
143.
144.
Xie C et al (2014) NONCODEv4: exploring the world of long non-coding RNA genes. Nucleic Acids Res 42(Database issue):D98–D103PubMedCrossRef
145.
Fok ET et al (2017) The emerging molecular biology toolbox for the study of long noncoding RNA biology. Epigenomics 9(10):1317–1327PubMedCrossRef
146.
Thomson DW, Dinger ME (2016) Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet 17(5):272–283PubMedCrossRef
147.
148.
de Lara JC, Arzate-Mejia RG, Recillas-Targa F (2019) Enhancer RNAs: insights Into Their Biological Role. Epigenet Insights 12:2516865719846093PubMedPubMedCentral
149.
Terracciano D et al (2017) The role of a new class of long noncoding RNAs transcribed from ultraconserved regions in cancer. Biochim Biophys Acta Rev Cancer 1868(2):449–455PubMedCrossRef
150.
Jarroux J, Morillon A, Pinskaya M (2017) History, discovery, and classification of lncRNAs. Adv Exp Med Biol 1008:1–46PubMedCrossRef
151.
152.
153.
Bak RO, Mikkelsen JG (2014) miRNA sponges: soaking up miRNAs for regulation of gene expression. Wiley Interdiscip Rev RNA 5(3):317–333PubMedCrossRef
154.
Meseure D et al (2016) Expression of ANRIL-polycomb complexes-CDKN2A/B/ARF genes in breast tumors: identification of a two-gene (EZH2/CBX7) signature with independent prognostic value. Mol Cancer Res 14(7):623–633PubMedCrossRef
155.
Zhou X et al (2016) Long non-coding RNA ANRIL regulates inflammatory responses as a novel component of NF-kappaB pathway. RNA Biol 13(1):98–108PubMedCrossRef
156.
Motterle A et al (2012) Functional analyses of coronary artery disease associated variation on chromosome 9p21 in vascular smooth muscle cells. Hum Mol Genet 21(18):4021–4029PubMedPubMedCentralCrossRef
157.
Holdt LM et al (2013) Alu elements in ANRIL non-coding RNA at chromosome 9p21 modulate atherogenic cell functions through trans-regulation of gene networks. PLoS Genet 9(7):e1003588PubMedPubMedCentralCrossRef
158.
Xu ST et al (2017) Long non-coding RNA ANRIL promotes carcinogenesis via sponging miR-199a in triple-negative breast cancer. Biomed Pharmacother 96:14–21PubMedCrossRef
159.
160.
Zhang H, Wang X, Chen X (2017) Potential role of long non-coding RNA ANRIL in pediatric medulloblastoma through promotion on proliferation and migration by targeting miR-323. J Cell Biochem 118(12):4735–4744PubMedCrossRef
161.
Xiao X et al (2017) LncRNA MALAT1 sponges miR-204 to promote osteoblast differentiation of human aortic valve interstitial cells through up-regulating Smad4. Int J Cardiol 243:404–412PubMedCrossRef
162.
Sun JY et al (2017) Knockdown of MALAT1 expression inhibits HUVEC proliferation by upregulation of miR-320a and downregulation of FOXM1 expression. Oncotarget 8(37):61499–61509PubMedPubMedCentralCrossRef
163.
Zhong X et al (2018) MIAT promotes proliferation and hinders apoptosis by modulating miR-181b/STAT3 axis in ox-LDL-induced atherosclerosis cell models. Biomed Pharmacother 97:1078–1085PubMedCrossRef
164.
Ye ZM et al (2019) LncRNA MIAT sponges miR-149-5p to inhibit efferocytosis in advanced atherosclerosis through CD47 upregulation. Cell Death Dis 10(2):138PubMedPubMedCentralCrossRef
165.
Bai Y et al (2019) Modulation of the proliferation/apoptosis balance of vascular smooth muscle cells in atherosclerosis by lncRNA-MEG3 via regulation of miR-26a/Smad1 axis. Int Heart J 60(2):444–450PubMedCrossRef
166.
Zhang Y et al (2018) Melatonin prevents endothelial cell pyroptosis via regulation of long noncoding RNA MEG3/miR-223/NLRP3 axis. J Pineal Res 64(2):e12449CrossRef
167.
Miao C et al (2018) LncRNA DIGIT accelerates tube formation of vascular endothelial cells by sponging miR-134. Int Heart J 59(5):1086–1095PubMedCrossRef
168.
Ye J et al (2018) LncRBA GSA5, up-regulated by ox-LDL, aggravates inflammatory response and MMP expression in THP-1 macrophages by acting like a sponge for miR-221. Exp Cell Res 369(2):348–355PubMedCrossRef
169.
Bao MH et al (2018) Long noncoding RNA LINC00657 acting as a miR-590-3p sponge to facilitate low concentration oxidized low-density lipoprotein-induced angiogenesis. Mol Pharmacol 93(4):368–375PubMedCrossRef
170.
Yu C et al (2018) LncRNA TUG1 sponges miR-204-5p to promote osteoblast differentiation through upregulating Runx2 in aortic valve calcification. Cardiovasc Res 114(1):168–179PubMedCrossRef
171.
Liu Y et al (2019) Linc00299/miR-490-3p/AURKA axis regulates cell growth and migration in atherosclerosis. Heart Vessels 34(8):1370–1380PubMedCrossRef
172.
Tian S et al (2018) LncRNA UCA1 sponges miR-26a to regulate the migration and proliferation of vascular smooth muscle cells. Gene 673:159–166PubMedCrossRef
173.
Zhang BY, Jin Z, Zhao Z (2017) Long intergenic noncoding RNA 00305 sponges miR-136 to regulate the hypoxia induced apoptosis of vascular endothelial cells. Biomed Pharmacother 94:238–243PubMedCrossRef
174.
175.
Zhang L et al (2018) H19 knockdown suppresses proliferation and induces apoptosis by regulating miR-148b/WNT/beta-catenin in ox-LDL -stimulated vascular smooth muscle cells. J Biomed Sci 25(1):11PubMedPubMedCentralCrossRef
176.
177.
178.
179.
Afify AY et al (2019) Competing endogenous RNAs in hepatocellular carcinoma-the Pinnacle of Rivalry. Semin Liver Dis 39:463–475PubMedCrossRef
180.
Cai Y, Wan J (2018) Competing endogenous RNA regulations in neurodegenerative disorders: current challenges and emerging insights. Front Mol Neurosci 11:370PubMedPubMedCentralCrossRef
181.
Ebbesen KK, Hansen TB, Kjems J (2017) Insights into circular RNA biology. RNA Biol 14(8):1035–1045PubMedCrossRef
182.
Ebbesen KK, Kjems J, Hansen TB (2016) Circular RNAs: identification, biogenesis and function. Biochim Biophys Acta 1859(1):163–168PubMedCrossRef
183.
184.
Zhou MY, Yang JM, Xiong XD (2018) The emerging landscape of circular RNA in cardiovascular diseases. J Mol Cell Cardiol 122:134–139PubMedCrossRef
185.
Li M et al (2019) Long noncoding RNA/circular noncoding RNA-miRNA-mRNA axes in cardiovascular diseases. Life Sci 233:116440PubMedCrossRef
186.
187.
Feng J et al (2006) The Evf-2 noncoding RNA is transcribed from the Dlx-5/6 ultraconserved region and functions as a Dlx-2 transcriptional coactivator. Genes Dev 20(11):1470–1484PubMedPubMedCentralCrossRef
188.
Lujambio A et al (2010) CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. Oncogene 29(48):6390–6401PubMedPubMedCentralCrossRef
189.
190.
Braconi C et al (2011) Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proc Natl Acad Sci USA 108(2):786–791PubMedCrossRef
191.
Wang C et al (2017) TUC.338 promotes invasion and metastasis in colorectal cancer. Int J Cancer 140(6):1457–1464PubMedCrossRef
192.
Marini A et al (2017) Ultraconserved long non-coding RNA uc.63 in breast cancer. Oncotarget 8(22):35669–35680PubMedCrossRef
193.
Liz J et al (2014) Regulation of pri-miRNA processing by a long noncoding RNA transcribed from an ultraconserved region. Mol Cell 55(1):138–147PubMedCrossRef
194.
Xiao L et al (2018) Long noncoding RNA uc.173 promotes renewal of the intestinal mucosa by inducing degradation of microRNA 195. Gastroenterology 154(3):599–611PubMedCrossRef
195.
Wang JY et al (2018) Regulation of intestinal epithelial barrier function by long noncoding RNA uc173 through interaction with MicroRNA 29b. Mol Cell Biol 38(13):e00010-18PubMedPubMedCentralCrossRef
196.
Nishizawa M et al. (2015) Post-transcriptional inducible gene regulation by natural antisense RNA. Front Biosci (Landmark Ed) 20:1–36CrossRef
197.
Gao YF et al (2020) LncRNA FOXD1-AS1 acts as a potential oncogenic biomarker in glioma. CNS Neurosci Ther 26:66–75PubMedCrossRef
198.
199.
Wang J et al (2017) TSPAN31 is a critical regulator on transduction of survival and apoptotic signals in hepatocellular carcinoma cells. FEBS Lett 591(18):2905–2918PubMedCrossRef
200.
Esnault C, Maestre J, Heidmann T (2000) Human LINE retrotransposons generate processed pseudogenes. Nat Genet 24(4):363–367PubMedCrossRef
201.
Kovalenko TF, Patrushev LI (2018) Pseudogenes as functionally significant elements of the genome. Biochemistry (Mosc) 83(11):1332–1349CrossRef
202.
Hu X, Yang L, Mo YY (2018) Role of pseudogenes in tumorigenesis. Cancers (Basel) 10(8):256CrossRef
203.
204.
205.
Zhang Z, Harrison P, Gerstein M (2002) Identification and analysis of over 2000 ribosomal protein pseudogenes in the human genome. Genome Res 12(10):1466–1482PubMedPubMedCentralCrossRef
206.
Li X et al (2019) LncRNA PMS2L2 protects ATDC5 chondrocytes against lipopolysaccharide-induced inflammatory injury by sponging miR-203. Life Sci 217:283–292PubMedCrossRef
207.
Wang R et al (2018) Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1. J Cell Mol Med 22(9):4068–4075PubMedPubMedCentralCrossRef
208.
Zhang CZ (2017) Long non-coding RNA FTH1P3 facilitates oral squamous cell carcinoma progression by acting as a molecular sponge of miR-224-5p to modulate fizzled 5 expression. Gene 607:47–55PubMedCrossRef
209.
Wang L et al (2013) Pseudogene OCT4-pg4 functions as a natural micro RNA sponge to regulate OCT4 expression by competing for miR-145 in hepatocellular carcinoma. Carcinogenesis 34(8):1773–1781PubMedCrossRef
210.
Gao L et al (2017) PTENp1, a natural sponge of miR-21, mediates PTEN expression to inhibit the proliferation of oral squamous cell carcinoma. Mol Carcinog 56(4):1322–1334PubMedCrossRef
211.
Zhang R et al (2017) Long non-coding RNA PTENP1 functions as a ceRNA to modulate PTEN level by decoying miR-106b and miR-93 in gastric cancer. Oncotarget 8(16):26079–26089PubMedPubMedCentral
212.
213.
214.
215.
216.
Chen LL, Yang L (2017) ALUternative regulation for gene expression. Trends Cell Biol 27(7):480–490PubMedCrossRef
217.
Navarro E et al (1999) Expressed sequence tag (EST) phenotyping of HT-29 cells: cloning of ser/thr protein kinase EMK1, kinesin KIF3B, and of transcripts that include Alu repeated elements. Biochim Biophys Acta 1450(3):254–264PubMedCrossRef
218.
Daniel C, Behm M, Ohman M (2015) The role of Alu elements in the cis-regulation of RNA processing. Cell Mol Life Sci 72(21):4063–4076PubMedCrossRef
219.
Pandey R, Mukerji M (2011) From ‘JUNK’ to just unexplored noncoding knowledge: the case of transcribed Alus. Brief Funct Genomics 10(5):294–311PubMedCrossRef
220.
Daskalova E et al (2007) 3′UTR-located ALU elements: donors of potential miRNA target sites and mediators of network miRNA-based regulatory interactions. Evol Bioinform Online 2:103–120PubMedPubMedCentral
221.
Smalheiser NR, Torvik VI (2006) Alu elements within human mRNAs are probable microRNA targets. Trends Genet 22(10):532–536PubMedCrossRef
222.
Pandey R et al (2016) Alu-miRNA interactions modulate transcript isoform diversity in stress response and reveal signatures of positive selection. Sci Rep 6:32348PubMedPubMedCentralCrossRef
223.
Hoffman Y et al (2014) miR-661 downregulates both Mdm2 and Mdm4 to activate p53. Cell Death Differ 21(2):302–309PubMedCrossRef
224.
Di Ruocco F et al (2018) Alu RNA accumulation induces epithelial-to-mesenchymal transition by modulating miR-566 and is associated with cancer progression. Oncogene 37(5):627–637PubMedCrossRef
225.
Zhao J et al (2015) High-throughput sequencing of RNAs isolated by cross-linking immunoprecipitation (HITS-CLIP) reveals Argonaute-associated microRNAs and targets in Schistosoma japonicum. Parasit Vectors 8:589PubMedPubMedCentralCrossRef
226.
Imig J et al (2015) miR-CLIP capture of a miRNA targetome uncovers a lincRNA H19-miR-106a interaction. Nat Chem Biol 11(2):107–114PubMedCrossRef
227.
Petri R, Jakobsson J (2018) Identifying miRNA targets using AGO-RIPseq. Methods Mol Biol 1720:131–140PubMedCrossRef
228.
229.
Tan SM, Lieberman J (2016) Capture and identification of miRNA targets by biotin pulldown and RNA-seq. Methods Mol Biol 1358:211–228PubMedCrossRef
230.
Hannigan MM, Zagore LL, Licatalosi DD (2018) Mapping transcriptome-wide protein-RNA interactions to elucidate RNA regulatory programs. Quant Biol 6(3):228–238PubMedPubMedCentralCrossRef
231.
Clement T, Salone V, Rederstorff M (2015) Dual luciferase gene reporter assays to study miRNA function. Methods Mol Biol 1296:187–198PubMedCrossRef
232.
Monga I, Kumar M (2019) Computational resources for prediction and analysis of functional miRNA and their targetome. Methods Mol Biol 1912:215–250PubMedCrossRef
233.
Riffo-Campos AL, Riquelme I, Brebi-Mieville P (2016) Tools for sequence-based miRNA target prediction: what to choose? Int J Mol Sci 17(12):1987PubMedCentralCrossRef
234.
235.
Roberts JT, Borchert GM (2017) Computational prediction of MicroRNA target genes, target prediction databases, and web resources. Methods Mol Biol 1617:109–122PubMedCrossRef
236.
Fridrich A, Hazan Y, Moran Y (2019) Too many false targets for MicroRNAs: challenges and pitfalls in prediction of miRNA targets and their gene ontology in model and non-model organisms. BioEssays 41(4):e1800169PubMedPubMedCentralCrossRef
237.
Wagner M et al (2014) MicroRNA target prediction: theory and practice. Mol Genet Genomics 289(6):1085–1101PubMedCrossRef
238.
239.
Dweep H, Gretz N (2015) miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods 12(8):697PubMedCrossRef
240.
241.
Andres-Leon E, Rojas AM (2019) miARma-Seq, a comprehensive pipeline for the simultaneous study and integration of miRNA and mRNA expression data. Methods 152:31–40PubMedCrossRef
242.
Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30(1):207–210PubMedPubMedCentralCrossRef
243.
Zhang Y et al (2018) Effects of icariin on atherosclerosis and predicted function regulatory network in apoe deficient mice. Biomed Res Int 2018:9424186PubMedPubMedCentral
244.
Gene Ontology, C (2015) Gene Ontology Consortium: going forward. Nucleic Acids Res 43(Database issue):D1049–D1056CrossRef
245.
Khyzha N et al (2017) Epigenetics of atherosclerosis: emerging mechanisms and methods. Trends Mol Med 23(4):332–347PubMedCrossRef
246.
Parikh N, Frishman WH (2010) Liver x receptors: a potential therapeutic target for modulating the atherosclerotic process. Cardiol Rev 18(6):269–274PubMedCrossRef
247.
Wang HX, Zhao YX (2016) Prediction of genetic risk factors of atherosclerosis using various bioinformatic tools. Genet Mol Res 15(2):gmr7347
248.
249.
He L et al (2018) Uncovering novel landscape of cardiovascular diseases and therapeutic targets for cardioprotection via long noncoding RNA-miRNA-mRNA axes. Epigenomics 10(5):661–671PubMedCrossRef
250.
Kozomara A, Birgaoanu M, Griffiths-Jones S (2019) miRBase: from microRNA sequences to function. Nucleic Acids Res 47(D1):D155–D162PubMedCrossRef
251.
Chou CH et al (2018) miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res 46(D1):D296–D302PubMedCrossRef
252.
Sethupathy P, Corda B, Hatzigeorgiou AG (2006) TarBase: a comprehensive database of experimentally supported animal microRNA targets. RNA 12(2):192–197PubMedPubMedCentralCrossRef
253.
Paraskevopoulou MD et al (2013) DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows. Nucleic Acids Res 41(Web Server issue):W169–W173PubMedPubMedCentralCrossRef
254.
Blin K et al (2015) DoRiNA 2.0–upgrading the doRiNA database of RNA interactions in post-transcriptional regulation. Nucleic Acids Res 43(Database issue):D160–D167PubMedCrossRef
255.
256.
Tsang JS, Ebert MS, van Oudenaarden A (2010) Genome-wide dissection of microRNA functions and cotargeting networks using gene set signatures. Mol Cell 38(1):140–153PubMedPubMedCentralCrossRef
257.
Wong N, Wang X (2015) miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res 43(Database issue):D146–D152PubMedCrossRef
258.
259.
Hsu SD et al (2008) miRNAMap 2.0: genomic maps of microRNAs in metazoan genomes. Nucleic Acids Res 36(Database issue):D165–D169PubMed
260.
261.
Kertesz M et al (2007) The role of site accessibility in microRNA target recognition. Nat Genet 39(10):1278–1284PubMedCrossRef
262.
Chang TH et al (2013) An enhanced computational platform for investigating the roles of regulatory RNA and for identifying functional RNA motifs. BMC Bioinform 14(Suppl 2):S4CrossRef
263.
Miranda KC et al (2006) A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 126(6):1203–1217PubMedCrossRef
264.
265.
266.
Nam S et al (2009) MicroRNA and mRNA integrated analysis (MMIA): a web tool for examining biological functions of microRNA expression. Nucleic Acids Res 37(Web Server issue):W356–W362PubMedPubMedCentralCrossRef
267.
Paraskevopoulou MD et al (2013) DIANA-LncBase: experimentally verified and computationally predicted microRNA targets on long non-coding RNAs. Nucleic Acids Res 41(Database issue):D239–D245PubMedCrossRef
268.
269.
Eraslan G et al (2019) Deep learning: new computational modelling techniques for genomics. Nat Rev Genet 20(7):389–403PubMedCrossRef
270.
271.
Jaganathan K et al (2019) Predicting splicing from primary sequence with deep learning. Cell 176(3):535–548.e24PubMedCrossRef
Metadata
Title
Unveiling ncRNA regulatory axes in atherosclerosis progression
Authors
Estanislao Navarro
Adrian Mallén
Josep M. Cruzado
Joan Torras
Miguel Hueso
Publication date
01-12-2020
Publisher
Springer Berlin Heidelberg
Published in
Clinical and Translational Medicine / Issue 1/2020
Electronic ISSN: 2001-1326
DOI
https://doi.org/10.1186/s40169-020-0256-3

Other articles of this Issue 1/2020

Clinical and Translational Medicine 1/2020 Go to the issue

Research

The novel llama-human chimeric antibody has potent effect in lowering LDL-c levels in hPCSK9 transgenic rats

Review

The clinical potential of gene editing as a tool to engineer cell-based therapeutics

Research

Personalized CT-based radiomics nomogram preoperative predicting Ki-67 expression in gastrointestinal stromal tumors: a multicenter development and validation cohort

Research

Computational determination of human PPARG gene: SNPs and prediction of their effect on protein functions of diabetic patients

Research

Embryos derived from donor or patient oocytes are not different for in vitro fertilization outcomes when PGT allows euploid embryo selection: a retrospective study

Review

2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies